Valuation: Rapport Therapeutics, Inc.

Market Cap 2.28B 1.96B 1.84B 1.68B 3.16B 218B 3.2B 21.6B 8.46B 109B 8.54B 8.36B 363B P/E 2026 *
-11.7x
P/E 2027 * -9.67x
Enterprise Value 1.95B 1.68B 1.58B 1.44B 2.7B 186B 2.74B 18.48B 7.24B 93.22B 7.31B 7.15B 310B EV / Sales 2026 *
97.3x
EV / Sales 2027 * -
Free-Float
95.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.11%
1 week+6.44%
Current month+18.16%
1 month+20.66%
3 months+30.62%
6 months+73.36%
Current year+59.59%
1 week 46.35
Extreme 46.35
49.5
1 month 39.75
Extreme 39.75
49.5
Current year 25.21
Extreme 25.21
49.5
1 year 13.86
Extreme 13.86
49.5
3 years 6.43
Extreme 6.43
49.5
5 years 6.43
Extreme 6.43
49.5
10 years 6.43
Extreme 6.43
49.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 31/12/2022
Chief Executive Officer 48 31/01/2023
Director of Finance/CFO 58 31/10/2023
Director TitleAgeSince
Director/Board Member 61 22/08/2023
Director/Board Member 48 28/02/2023
Director/Board Member 54 31/01/2022
Date Insider Type Main position Quantity % Market Cap.
11/08/26 Sell

Chief Executive Officer

-28,958 0.0605%
27/07/26 Sell

Chief Executive Officer

-2,210 0.0046%
14/07/26 Sell

Chief Executive Officer

-8,210 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%+6.44%+229.28% - 2.28B
+0.68%-1.01%+2.16%+18.05% 48.42B
+4.07%+3.34%+483.70%+609.03% 43.66B
+4.33%+4.09%+12.80%+88.48% 39.51B
+1.94%+1.06%+26.24%+12.10% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.44%-3.14% - - 16.32B
+3.22%+1.09%+30.42%+133.64% 16.15B
-0.62%+0.29%+3.46%+25.58% 14.16B
+2.35%+7.16%+82.95%+41.92% 13.37B
Average +1.71%+0.11%+99.07%+123.37% 26.54B
Weighted average by Cap. +1.93%-0.58%+102.75%+147.52%

Financials

2026 *2027 *
Net sales 20M 17.27M 16.2M 14.75M 27.74M 1.91B 28.13M 190M 74.41M 958M 75.09M 73.46M 3.19B -
Net income -194M -168M -157M -143M -269M -18.56B -273M -1.84B -722M -9.3B -729M -713M -30.93B -252M -218M -204M -186M -350M -24.13B -355M -2.4B -939M -12.09B -948M -927M -40.22B
Net Debt -329M -284M -267M -243M -456M -31.47B -463M -3.12B -1.22B -15.76B -1.24B -1.21B -52.44B -477M -412M -386M -352M -661M -45.58B -670M -4.53B -1.77B -22.83B -1.79B -1.75B -75.96B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
17/08/26 US$48.42 +2.11% 203,641
14/08/26 US$47.42 +0.13% 159,831
13/08/26 US$47.36 -0.78% 242,095
12/08/26 US$47.73 -2.23% 316,898
11/08/26 US$48.82 +3.92% 425,321
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
48.42USD
Average target price
62.05USD
Spread / Average Target
+28.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock